At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 217 enrolled
Drug / intervention
Dexlansoprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)
In Brief
A Phase 3 clinical trial evaluating Dexlansoprazole and Placebo for Heartburn and Gastroesophageal Reflux Disease. Completed, enrolled 217 participants across 25 sites.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of dexlansoprazole compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in Chinese participants with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeartburn, Gastroesophageal Reflux Disease
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartDec 2016
Primary CompletionMar 2018
Study CompletionApr 2018
TodayJul 2026
First PostedAug 19, 2016
Enrollment StartDec 27, 2016
Primary CompletionMar 14, 2018
Study CompletionApr 19, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.9 years ago
Interventions
Dexlansoprazoledrug
Dexlansoprazole delayed-release capsule
Placebodrug
Dexlansoprazole placebo-matching capsules